Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc.

RNANYSE / NASDAQHealthcareSmall cap

$6.92-$0.06 (-0.9%)

Last close · Data as of Nov 20, 2026

Market cap
$210.4M
P/E
-2.7x
EV / EBITDA
0.7x
Revenue
$18.6M
Net margin
-411.9%
ROCE
-32.5%

A period is left blank when the price history is shorter than the period.

Atrium Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-13.3%
3M
-48.7%
6M
-45.6%
1Y
Short history
5Y
Short history
  • A period is left blank when the price history is shorter than the period.

52-week range

Day change -$0.06 (-0.9%) from $7 to $7 · Last close Nov 20, 2026

News & filings

What Atrium Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 76.7 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue grew 70.9% in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.

Sector
Healthcare
Shares outstanding
17.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$210.4M
P/E
-2.7x
P/B
1.0x
EV / EBITDA
0.7x
EV / Sales
-3.0x
P/S
11.3x
52-week high
$16.54
52-week low
$6.43

Profitability

Operating margin
-412.6%
Net margin
-411.9%
EBITDA margin
-410.8%
ROE
-37.0%
ROCE
-32.5%
ROA
-27.5%
Asset turnover
0.07

Growth

Revenue
$18.6M
Revenue growth, 1Y
70.9%
Net profit growth, 1Y
205.2%
Free cash flow
-$42.6M

Solvency

Current ratio
6.53
Debt / Equity
0.02
Debt / Assets
0.01
CFO / Net profit
0.54
Cash / Market cap
128.3%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$18.6M
Gross profit$18.6M
Operating expenses$95.4M
Research and development$53.8M
Selling, general and administrative$41.7M
Operating income-$76.8M
Interest and other-$20.0k
Pretax income-$76.8M
Tax and other-$150.0k
Net income-$76.7M

Revenue and net profit

Revenue grew 70.9% in FY2025; net profit is the dashed line.

Atrium Therapeutics, Inc. revenue and net profit by fiscal year
Atrium Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2023$9.8M-$6.4M
FY2024$10.9M-$25.1M
FY2025$18.6M-$76.7M

Cash flows

FY2025: -$41.1M from operations, -$42.6M free after investment (dashed).

Atrium Therapeutics, Inc. operating and free cash flow by fiscal year
Atrium Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2023$56.4M$56.1M
FY2024-$22.6M-$22.8M
FY2025-$41.1M-$42.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$18.6M+70.9%1Y
EBITDA
-$76.5M
Net profit
-$76.7M
Cash from operations
-$41.1M
Free cash flow
-$42.6M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$18.6M-$76.5M-$76.7M-$42.6M-37.0%+70.9%+205.2%

Monthly returns

Month-by-month returns of RNA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$278.4M
Liabilities$71.1M
Equity$207.3M
Paid-in capital$207.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; RNA highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Atrium Therapeutics, Inc. (this company)-3.0x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Atrium Therapeutics, Inc.RNAthis company$210.4M-2.7x1.0x-37.0%0.7x
Utah Medical Products, Inc.UTMD$216.5M19.2x1.8x9.5%9.1x
Pro-Dex, Inc.PDEX$213.9M23.8x5.8x24.5%16.3x
Keros Therapeutics, Inc.KROS$213.2M2.4x0.7x28.7%-0.8x
RxSight, Inc.RXST$211.1M-5.4x0.8x-14.1%-5.7x
Accendra Health, Inc.ACH$202.9M-0.2x-0.4x238.8%9.3x
Sanara MedTech Inc.SMTI$202.7M-5.4x34.1x-632.5%22.7x
TriSalus Life Sciences, Inc.TLSI$202.7M-5.2x-6.0x115.8%-6.6x
Embecta Corp.EMBC$202.3M2.1x-0.3x-14.6%4.9x
Peer median—1.0x0.7x17.0%7.0x

Year-to-date ROI

RNA since 1 January, against earlier years.

Historical volatility

RNA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Atrium Therapeutics, Inc. operating margin by fiscal year
Atrium Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2023-65.5%
FY2024-121.3%
FY2025-412.5%
LineFY2025
Operating expensesOperating Expense$95.4M
Research and developmentResearch And Development$53.8M
Total expensesTotal Expenses$95.4M
Pretax incomePretax Income-$76.8M

Learn while you research

Academy chapters picked for Atrium Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing71% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →